Welcome to the home page of ADDMAL09 research project!
Malaria, the most common infectious disease, is transmitted by Anopheles mosquitoes and caused by Plasmodium parasites. According to the WHO, there were an estimated 250 million malaria cases in 2006 causing at least one million deaths, mostly of children under 5 years. In Africa a child dies every 30 seconds of Malaria, the disease accounts for 20% of all childhood deaths. Despite of the new generation of drugs and combined therapies resistance in the malaria parasite to drugs (including Artemisin) is common. Therefore a major goal of malaria research is to find drugs with novel targets and a novel mechanism of action. In parallel, more research is needed to elucidate mechanisms of drug resistance, since new drugs should not only be effective, but should also evade mechanisms that contribute to parasite resistance.
Diagnostics is another major issue in Malaria research. As Bill and Melinda Gates Foundation states: „Diagnostics…could save 1.8 million lives and prevent 396 million unnecessary treatments”. According to the WHO guideline: “Currently, there are no bedside tests for determining the susceptibility of the malaria parasite to antimalarials“ and “In all settings, clinical suspicion of malaria should be confirmed with a parasitological diagnosis.” „the results of parasitological diagnosis should be available within a short time (less than two hours) of the patient presenting.”
These statements indicate a huge opportunity for developers. Indeed there is a huge unmet need for diagnostic assays being able to meet current international recommendations for case confirmation and/or for malaria monitoring.
The ADDMAL09 research consortium will characterize essential proteins of the parasite; identify compounds targeting these enyzmes; evaluate drug resistance caused by the Pgh-1 transporter; and finally, determine the interactions of select antimalaria compounds with human transporters shaping general ADME properties.
See more under section Research tasks